RVLP News and Press, RVL Pharmaceuticals plc From 08/30/22

BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at the H.C. Wainwright 24 th ...

RVL Pharmaceuticals plc ( NASDAQ: RVLP ), the maker of Upneeq eye disease therapy, and Revision Skincare, an Irving, Texas-based seller of skin care products, announced a partnership on Tuesday to widen market access to their product offerings. Through the partnership, Rev...

DALLAS and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Revision Skincare ® , a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL”), the owner of UPNEEQ ® , the first and...

RVL Pharmaceuticals plc (RVLP) Q2 2022 Earnings Conference Call August 11, 2022, 08:30 AM ET Company Participants Lisa Wilson - IR Brian Markison - CEO Mike DePetris - Interim CFO JD Schaub - COO Conference Call Participants Louise Chen - Cantor ...

press release ( NASDAQ: RVLP ): Q2 GAAP EPS of -$0.14 beats by $0.07 . Revenue of $8.45M (-26.6% Y/Y) misses by $0.07M . “Our recent financing and addition of Alisa Lask to our Board of Directors are strong signals of our growing belief in UPNE...

-- Second quarter 2022 UPNEEQ ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings -- -- Expanded Board of Directors with the appointment of Alisa Lask, Ae...

-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing -- -- Cash runway anticipated to extend through 2023 with $43.9 million funded at closing and an additional $25.0 million of availability through April 2023, subject to a mi...

BRIDGEWATER, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%,...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2022, the stock market has faced a plethora of negative factors, from the Russian invasion of Ukraine and the soaring energy prices that followed to the historic high inflation, the shift in the monetary policy by the Fe...

Gainers: Seritage Growth Properties ( SRG ) +72% . Aditxt ( ADTX ) +70% . Humanigen ( HGEN ) +35% . Clovis Oncology ( CLVS ) +30% . MyMD Pharmaceuticals ( MYMD ) +27% . Oramed Pharmaceuticals ( ORMP ) +26% . Kura ...